Entrada Therapeutics Other Current Assets

Entrada Therapeutics posts a other current assets of $12M as of March 2026. That compares with $19M in the prior-year period — down 35.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Entrada Therapeutics's other current assets was $19M. The latest reading is $12M — a 35.5% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Other Current Assets is one piece of Entrada Therapeutics's financial statement story. At $12M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TRDA's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Entrada Therapeutics's other metric pages and overview cover the third.